Mitochondrial RNA in Alzheimer’s Disease Circulating Extracellular Vesicles

Kyoung Mi Kim1,2†, Qiong Meng1†, Olivia Perez de Acha1, Maja Mustapic3, Aiwu Cheng1, Erden Eren3, Gautam Kundu1, Yulan Piao1, Rachel Munk1, William H. Wood III1, Supriyo De1, Ji Heon Noh4, Michael Delannoy5, Lesley Cheng6, Kotb Abdelmohsen1, Dimitrios Kapogiannis3* and Myriam Gorospe1*

1 Laboratory of Genetics and Genomics, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD, United States, 2 Department of Biological Sciences, Chungnam National University, Daejeon, South Korea, 3 Laboratory of Clinical Investigation, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD, United States, 4 Department of Biochemistry, Chungnam National University, Daejeon, South Korea, 5 Department of Cell Biology and Imaging Facility, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 6 Department of Biochemistry and Genetics, School of Molecular Science, La Trobe University, Melbourne, VIC, Australia

Alzheimer’s disease (AD) is the most common type of dementia. Amyloid β (Aβ) plaques, tau-containing neurofibrillary tangles, and neuronal loss leading to brain atrophy are pathologic hallmarks of AD. Given the importance of early diagnosis, extensive efforts have been undertaken to identify diagnostic and prognostic biomarkers for AD. Circulating extracellular vesicles (EVs) provide a platform for “liquid biopsy” biomarkers for AD. Here, we characterized the RNA contents of plasma EVs of age-matched individuals who were cognitively normal (healthy controls (HC)) or had mild cognitive impairment (MCI) due to AD or had mild AD dementia (AD). Using RNA sequencing analysis, we found that mitochondrial (mt)-RNAs, including MT-ND1-6 mRNAs and other protein-coding and non-coding mt-RNAs, were strikingly elevated in plasma EVs of MCI and AD individuals compared with HC. EVs secreted from cultured astrocytes, microglia, and neurons after exposure to toxic conditions relevant to AD pathogenesis (Aβ aggregates and H2O2), contained mitochondrial structures (detected by electron microscopy) and mitochondrial RNA and protein. We propose that in the AD brain, toxicity-causing mitochondrial damage results in the packaging of mitochondrial components for export in EVs and further propose that mt-RNAs in plasma EVs can be diagnostic and prognostic biomarkers for MCI and AD.

Keywords: extracellular vesicles, Alzheimer’s disease, mitochondrial protein, mitochondrial RNA, biomarker

INTRODUCTION

Alzheimer’s disease (AD) is the leading age-associated neurodegenerative disease. The disease is associated with numerous structural and functional alterations involving not only neurons but also all other brain cells (Weller and Budson, 2018). Currently, most accepted disease biomarkers relate to the main pathologic hallmarks of the disease: amyloid β (Aβ) plaques (A), MAPT protein (tau) neurofibrillary tangles (T), and neurodegeneration (N). These biomarkers, codified into the A/T/N system, are assessed through invasive and/or expensive tests including cerebrospinal fluid
(CSF) sampling and positron emission tomography (PET) scans (Jack et al., 2016). Therefore, extensive efforts are underway to identify robust, specific, sensitive, and easily accessible indicators of AD, particularly at its mild cognitive impairment (MCI) prodromal stage or even preclinically (Sperling et al., 2011; Dubois et al., 2016). In addition to their importance for clinical practice, such biomarkers might inform us about the molecular neuropathology of AD and provide us with novel therapeutic targets.

Extracellular vesicles (EVs) include exosomes (30–150 nm in diameter), which originate from late endosomes and are released from cytoplasmic multivesicular bodies (MVBs) fusing with the plasma membrane, microvesicles (100–1,000 nm in diameter) that originate by budding of the plasma membrane, and apoptotic bodies (reaching up to 5,000 nm in diameter) (Raposo and Stoorvogel, 2013; van Niel et al., 2018). They transport diverse cargo molecules (DNA, RNA, protein, bioactive lipids, etc.) and are believed to have a variety of functions, including disposal of cellular waste and intercellular communication (Hill, 2019). EVs are found in body fluids such as blood, breast milk, amniotic fluid, urine, and saliva (Armstrong and Wildman, 2018) and are produced by all cell types, including neurons, astrocytes, and microglia (Holm et al., 2018; Hill, 2019). The composition, size, and concentration of EVs, and their rate of release vary depending on the cell type and pathophysiological conditions. Accordingly, EV contents from many biological fluids are currently used as diagnostic or prognostic biomarkers. For example, renal EVs detected in blood and urine contain proteins, mRNAs, and microRNAs that are altered with kidney disease and can be utilized as biomarkers (Stahl et al., 2019). Similarly, EVs have emerged as biomarkers in cancer and cardiovascular diseases (Dickhout and Koenen, 2018; Lane et al., 2018).

In the central nervous system (CNS), microglia, oligodendrocytes, neurons, and astrocytes have been found to release EVs (Holm et al., 2018, 2019). EVs have been reported to play key roles in the normal CNS (Caruso Bavisotto et al., 2019) and have been implicated in neurodegenerative diseases (Hill, 2019), particularly in the transport of the disease-associated α-synuclein throughout different brain regions (Coleman and Hill, 2015; Budnik et al., 2016; Thompson et al., 2016). Moreover, EVs may travel between the CNS and peripheral circulation and hence can be used as biomarkers for CNS disorders (Shi et al., 2019). In recent years, multiple studies have identified and validated protein cargo of neuronal and astrocytic EVs as biomarkers for AD (Goetzl et al., 2016, 2018; Cha et al., 2019; Kapogiannis et al., 2019b) and other neurological and even psychiatric disorders (Athauda et al., 2019; Bhargava et al., 2019, 2020; Chavla et al., 2019; Kapogiannis et al., 2019a; Mansur et al., 2020). Nevertheless, the rich cargo of EVs provide opportunities for discovering biomarkers that reflect other important aspects of disease pathogenesis.

While the molecular content of EVs can provide critical clues about the mechanisms that govern disease progression, they can also provide a powerful disease signature. The biomarker potential of EV cargo RNAs in AD has been explored mainly for microRNAs in EVs (Cheng et al., 2015; Cha et al., 2019; Lee et al., 2019). In this study, we analyzed the RNAs present in circulating EVs obtained from age-matched individuals who were cognitively normal (healthy controls (HC)), had MCI due to AD or had mild dementia due to AD (five donors per group). RNA-sequencing analysis indicated striking increases in the mitochondrial (mt)-RNA in MCI and AD compared with the HC individuals. This RNA abundance pattern was further validated using reverse transcription (RT) followed by quantitative (q)PCR analysis. As anticipated, the levels of several mt-RNAs including MT-ND1-6, MT-ND4L, MT-ATP6, MT-ATP8, MT-CYTb, MT-CO1, MT-CO2, MT-CO3 mRNAs, and MT-RNR1 mRNA were elevated in MCI and AD EVs relative to HC EVs, while glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA levels remained unchanged. We postulated that toxicity from Aβ and tau aggregates in the AD brain may cause mitochondrial damage in brain cells leading to the export of mitochondrial components to the extracellular space via EVs. To test this hypothesis, cultures derived from astrocytes, microglia, and neurons were incubated with Aβ oligomers, the toxic species in Aβ plaques, or with H2O2 to mimic the oxidative stress that occurs in the AD environment. EVs released into the respective media following Aβ or H2O2 treatment showed elevated mt-RNA levels, as well as elevated mitochondrial proteins and remnants of structures resembling mitochondria inside EVs. Together, these findings suggest that the circulating EVs from AD patients contain mitochondrial material, perhaps due to mitochondrial dysfunction that results from exposure to stressful stimuli. Our results further suggest that EV mt-RNAs in plasma may serve as biomarkers of early AD.

**MATERIALS AND METHODS**

**Human Subjects**

All participants donated blood as part of their participation in clinical studies at the National Institute on Aging (NIA) approved by the National Institutes of Health Institutional Review Board. All participants provided written informed consent. Procedures for sample collection and processing were identical for all samples. For RNA-sequencing analysis, we used five individuals with mild AD dementia, five with MCI due to AD, and five age- and sex-matched cognitively normal HC (Cohort 1, Table 1). For RT-qPCR analysis, we used another set of five individuals with mild AD dementia, five with MCI due to AD, and five HC individuals (Cohort 2, Table 1).

Individuals with MCI or mild AD dementia for both cohorts were participants in a clinical trial of exenatide in early AD1; Mullins et al., 2019); eligibility criteria included > 60 years old, clinical diagnosis of amnestic MCI or probable AD (with mild dementia), clinical dementia rating (CDR) global score of 0.5 or 1, low CSF Aβ42 < 192 pg/ml (using INNO-BIA Alz Bio3 kits), and absence of other neurological disorders or significant neuroimaging abnormalities. For the purpose of this study, we selected baseline samples (i.e., before randomization) of individuals that fulfill criteria for high probability AD

---

1https://clinicaltrials.gov/ct2/show/NCT01255163
TABLE 1 | Demographic, clinical, and biomarker characteristics of human subjects.

|                      | Normal | MCI | AD | p-value (AD vs. HC/AD vs. MCI) |
|----------------------|--------|-----|----|--------------------------------|
| Number of subjects   | 5      | 5   | 5  |                                |
| **Cohort 1**         |        |     |    |                                |
| Age [SD]             | 76.2 [5.97] | 76.0 [7.25] | 77.6 [8.35] | NS/NS                         |
| Sex (F/M)            | 2/3    | 2/3 | 2/3 | NS*                            |
| MMSE [SD]            | 29 [2.07] | 23 [2.51] | 19.4 [2.60] | 0.047                          |
| ADAS-70 [SD]         | 10 [6.19] | 16 [4.40] | 16 [6.40] | 0.000                          |
| CDR-Global [SD]      | 0.50 [0.00] | 0.60 [0.22] | 0.60 [0.14] | NS                            |
| CDR-Sob [SD]         | 1.70 [0.27] | 3.60 [1.64] | 3.60 [1.82] | 0.052                          |
| CSF tau (pg/ml) [SD] | 75.60 [15.47] | 108.80 [49.09] | 108.80 [49.09] | NS                            |
| CSF p181-tau (pg/ml) [SD] | 36.40 [11.41] | 71.00 [35.77] | 71.00 [35.77] | 0.075                          |
| **Cohort 2**         |        |     |    |                                |
| Age [SD]             | 75.8    | 66.40 [8.78] | 74.60 [8.39] | 0.075                          |
| Sex (F/M)            | 3/2    | 4/1 | 3/2 | NS/0.003*                      |
| MMSE [SD]            | 25.40 [4.88] | 18.60 [8.68] | 18.60 [8.68] | NS                            |
| ADAS-70 [SD]         | 11.40 [6.23] | 22.20 [4.44] | 22.20 [4.44] | 0.028                          |
| CDR-Global [SD]      | 0.40 [0.22] | 1.20 [0.45] | 1.20 [0.45] | 0.005                          |
| CDR-Sob [SD]         | 2.60 [1.92] | 6.20 [1.82] | 6.20 [1.82] | 0.009                          |
| CSF tau (pg/ml) [SD] | 63.40 [13.59] | 105.00 [66.28] | 105.00 [66.28] | NS                            |
| CSF p181-tau (pg/ml) [SD] | 56.40 [14.54] | 95.40 [35.21] | 95.40 [35.21] | NS                            |
| CSF Aβ 1–42 (pg/ml) [SD] | 184.80 [26.57] | 178.40 [22.28] | 178.40 [22.28] | NS                            |

Pairwise comparisons between groups were conducted with t-test for continuous variables and Chi-square for categorical variables. NS corresponds to p > 0.1. *Chi-square.

Reverse Transcription and Real-Time Quantitative (q)PCR Analysis From EVs

For validation studies, plasma was collected from a separate set of individuals (five HC, five MCI, and five AD). EVs isolated from individual subjects were not pooled, and their effects were assessed and analyzed separately to respect their biological variability.

For RT-qPCR validation of RNA in EVs, 1 ml each of thawed human plasma from five individuals per group (HC, MCI, and AD) was filtered using 0.8 µm Millex-AA syringe filters (Millipore) to eliminate larger particles including apoptotic bodies. EV RNA was then extracted using exoRNeasy Serum/Plasma Kit (QIAGEN) and used for cDNA synthesis using random hexamers and reverse transcriptase (Invitrogen). Gene-specific primers were then used for real-time quantitative (q)PCR amplification by employing SYBR Green master mix (Kapa Biosystems) and a QuantStudio 5 thermal cycler (Thermo Fisher Scientific). PCR primer pairs (each forward and reverse) were as follows:

- **mt-RNAs in AD EVs**

Based on clinical diagnosis of amnestic MCI or probable AD, low CSF Aβ42, high CSF total tau, and/or p181-tau (Albert et al., 2011; McKhann et al., 2011). Moreover, upon review of individual cases, individuals used for this study qualify as amyloid+/tau+/neurodegeneration+ according to the A/T/N framework (Jack et al., 2016). Normal controls were participants isolated from individual subjects were not pooled, and their participation; they have Blessed Information Memory

Demographic, clinical, and biomarker characteristics of human subjects.

Pairwise comparisons between groups were conducted with t-test for continuous variables and Chi-square for categorical variables. NS corresponds to p > 0.1. *Chi-square.

**RNA Sequencing Analysis From EVs in Human Plasma**

Plasma was isolated from five HC, five MCI, and five AD donors (Cohort 1). EV RNA was extracted from 4 ml of thawed human plasma using exoRNeasy Serum/Plasma Maxi kits (QIAGEN) and cDNA was prepared and amplified using the Ovation RNA-Seq System V2 (NuGEN) kit. The amplified cDNA was fragmented using a Bioruptor (Diagenode), adapters were ligated to cDNA using TruSeq ChiP Sample Preparation kit (Illumina, San Diego, CA, United States), the DNA fragments were size-selected (300–350 bp) after electrophoresis on a 2.5% agarose gel, the selected DNA was subjected to 17 cycles of PCR amplification, and library quality was determined using a Bioanalyzer 2100. The final libraries were subjected to paired-end sequencing (110 bases) using an Illumina HiSeq 2500 sequencer. FASTQ files were extracted using bcl2fastq v2.18.0.12, trimmed for adapter sequences using Cutadapt v1.18, and aligned to human genome hg19 Ensembl v82 using STAR software v2.4.0j. FeatureCounts was used to create gene counts from 15 samples. Differential expression analysis was carried out using edgeR library in R. Data are available at GSE153881.

Reverse Transcription and Real-Time Quantitative (q)PCR Analysis From EVs

For validation studies, plasma was collected from a separate set of individuals (five HC, five MCI, and five AD). EVs isolated from individual subjects were not pooled, and their effects were assessed and analyzed separately to respect their biological variability.

For RT-qPCR validation of RNA in EVs, 1 ml each of thawed human plasma from five individuals per group (HC, MCI, and AD) was filtered using 0.8 µm Millex-AA syringe filters (Millipore) to eliminate larger particles including apoptotic bodies. EV RNA was then extracted using exoRNeasy Serum/Plasma Kit (QIAGEN) and used for cDNA synthesis using random hexamers and reverse transcriptase (Invitrogen). Gene-specific primers were then used for real-time quantitative (q)PCR amplification by employing SYBR Green master mix (Kapa Biosystems) and a QuantStudio 5 thermal cycler (Thermo Fisher Scientific). PCR primer pairs (each forward and reverse) were as follows:

- **mt-RNAs in AD EVs**

Based on clinical diagnosis of amnestic MCI or probable AD, low CSF Aβ42, high CSF total tau, and/or p181-tau (Albert et al., 2011; McKhann et al., 2011). Moreover, upon review of individual cases, individuals used for this study qualify as amyloid+/tau+/neurodegeneration+ according to the A/T/N framework (Jack et al., 2016). Normal controls were participants isolated from individual subjects were not pooled, and their participation; they have Blessed Information Memory

Demographic, clinical, and biomarker characteristics of human subjects.

Pairwise comparisons between groups were conducted with t-test for continuous variables and Chi-square for categorical variables. NS corresponds to p > 0.1. *Chi-square.

**RNA Sequencing Analysis From EVs in Human Plasma**

Plasma was isolated from five HC, five MCI, and five AD donors (Cohort 1). EV RNA was extracted from 4 ml of thawed human plasma using exoRNeasy Serum/Plasma Maxi kits (QIAGEN) and cDNA was prepared and amplified using the Ovation RNA-Seq System V2 (NuGEN) kit. The amplified cDNA was fragmented using a Bioruptor (Diagenode), adapters were ligated to cDNA using TruSeq ChiP Sample Preparation kit (Illumina, San Diego, CA, United States), the DNA fragments were size-selected (300–350 bp) after electrophoresis on a 2.5% agarose gel, the selected DNA was subjected to 17 cycles of PCR amplification, and library quality was determined using a Bioanalyzer 2100. The final libraries were subjected to paired-end sequencing (110 bases) using an Illumina HiSeq 2500 sequencer. FASTQ files were extracted using bcl2fastq v2.18.0.12, trimmed for adapter sequences using Cutadapt v1.18, and aligned to human genome hg19 Ensembl v82 using STAR software v2.4.0j. FeatureCounts was used to create gene counts from 15 samples. Differential expression analysis was carried out using edgeR library in R. Data are available at GSE153881.
GGATGCAGGGATGTTTCT and GGTTGTGAACCCACCCATG and GTAGCTTGTGTTGGCCTAAAT for mt-Atp6 mRNA, GTATGGAGCACCACCATTTCC and CACCAGTAAAGATGTTGCTAA for mt-Co1 mRNA, AGGACCCAGAACAAC TACA and TGAGGCTGAGATGGGGTGAT for mt-Cytb mRNA, CACCTTGGACGGCCCATAAA and GAGTTGATGCGTGGT GCAATAA for mt-Nd1 mRNA, TGTTGTCTGGTGTTAGCA TFA and AACAGTACCAAAACCGCTTAA for mt-Nd6 mRNA, and CAGCCTATATACCGCCATCTTC and TTGGCTACACCT TGACCTAAC for mt-Rnr1 mRNA.

**Cell Culture and Treatment Conditions**

Immortalized human microglia HMC3 cells (ATCC CRL-3304), astrocytoma 1321N1 cells (Sigma-Aldrich; derived from human brain astrocytoma; Macintyre et al., 1972), and neuroblastoma SK-N-BE(2)-M17 (M17) (ATCC CRL-2267) cells were cultured in Eagle’s minimum essential medium (EMEM) or Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% antibiotics and antimycotics (Gibco).

For primary cultures of embryonic cortical neurons, timed-pregnant mice were obtained from The Jackson Laboratory. Cultures were prepared from embryonic day (E) 14.5 cerebral tissues as described (Zhao et al., 2019). Briefly, pregnant mice were killed by fast cervical dislocation, embryos and embryo brains were removed, and the cerebral hemisphere was dissected in sterile Hank’s balanced saline solution (HBSS). The collected brain tissues were incubated in 0.25% trypsin-EDTA for 30 min at 37°C and then transferred to DMEM containing 10% fetal bovine serum (DMEM+). The tissues were transferred to neurobasal (NB) medium containing B27 supplements, 2 mM l-glutamine, antibiotics and antimycotics (Gibco), and 1 mM HEPES and dissociated by trituration using a fire-polished Pasteur pipet. The dissociated cells were seeded into polyethyleneimine-coated plastic culture dishes at a density of 60,000 cells/cm² and cultured in the same B27-containing NB medium.

Before the collection of EVs from conditioned culture media, cells were incubated for 3 days in media containing exosome-depleted FBS (Gibco). Cell lines HMC3 and 1321N1 were treated for 3 days with either 50 or 100 µM hydrogen peroxide (H₂O₂; Sigma-Aldrich). H₂O₂ was diluted from a 10 mM stock solution in 2% uranyl acetate in maleate buffer for 1 h at 4°C. The samples were then centrifuged at 4°C for 20 min to remove debris and apoptotic bodies.

**Protein Analysis**

Proteins were extracted from whole-cell lysates or EVs using RIPA buffer (50 mM Tris-HCl (pH 7.2), 150 mM NaCl, 1% NP40, 0.1% SDS, 0.5% DOC, 1 mM PMSF, 25 mM MgCl₂) supplemented with a Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific). Following size fractionation using SDS-containing polyacrylamide gels, samples were transferred onto nitrocellulose membranes (Bio-Rad Laboratories). Primary antibodies recognizing TOMM20, COX IV, OPA1, and GAPDH (Cell Signaling Technology), CD81 (Abcam) and CD63 (BD Biosciences) were used. After incubation with appropriate secondary antibodies, protein signals were developed using enhanced chemiluminescence (ECL), and digitized images were captured using Kwik Quant Imager (Kindle Biosciences).

**Transmission Electron Microscopy**

Samples were adhered to Poly-L-Lysine-coated coverslips for 5 min, then fixed in 1% glutaraldehyde 80 mM phosphate buffer (Sorenson’s) containing 5 mM MgCl₂ at pH 7.4. One hour later, samples were placed in the same fixative with the pH shifted to 8.5 and fixed for 1 h at room temperature. Coverslips were rinsed in buffer containing sucrose then postfixed in potassium ferrocyanide-reduced osmium tetroxide for 1 h on ice. After phosphate and maleate buffer rinses, samples were stained en bloc in 2% uranyl acetate in maleate buffer for 1 h at 4°C. After a series of ethanol dehydrations (30–100%), samples were infiltrated with Eponate 12 (Polysciences) resin, embedded, and cured at 60°C for 48 h.

Coverslips mounted to inverted beam capsules were gently removed after soaking in liquid nitrogen for 10 min. Blocks were then trimmed and sectioned on a Riechert Ultracut E microtome with a Diatome Diamond knife (45°). Sections (70 nm) were picked up on formvar-coated 1 × 2 mm copper slot grids and stained with methanolic uranyl acetate followed by lead citrate. Grids were viewed on a Hitachi H 7600 TEM operating at 80 kV and digital images captured with an XR50 5 megapixel CCD camera from Advanced Microscopy Techniques Corp.
RESULTS

Increased Abundance of mt-RNAs in EVs From MCI and AD

Each group of HC, MCI, and AD individuals included three males (M) and two females (F) with mean ages of 76.2, 77.6, and 76 years, respectively (Cohort 1, section “Materials and Methods”; Figure 1A). As outlined in the workflow (Figure 1B), donor plasma samples were used to isolate total RNA from circulating EVs, which was then used to prepare cDNA libraries using a NuGEN kit (section “Materials and Methods”). Representative data of successful amplification using the ovation kit and reduction of distinct ribosomal RNA peaks are shown (Figures 1C,D). RNA sequencing (RNA-seq) analysis was performed as described (section “Materials and Methods”) with 110 bp paired-end directional reads.

RNA-seq analysis revealed a total of 15,215 transcripts in all EVs. The majority of RNAs (~80%) corresponded to coding transcripts (mRNAs), while non-coding RNAs (e.g., pseudogene RNAs, lincRNAs, mt-tRNAs, antisense RNAs, etc.) comprised ~20% of the total (Figure 2A and Supplementary Figure S1A). Comparisons of the EV RNAs from MCI relative to HC and from AD relative to HC individuals revealed many differentially abundant RNAs in these samples, as shown in the volcano plots (Figure 2B). Strikingly, mt-RNAs were among the most abundant RNAs in all samples; among mt-RNAs, we found 13 mRNAs, 22 tRNAs, and 2 rRNAs, all upregulated in MCI, and most of these are also upregulated in AD (Figure 2C). Non-coding RNAs transcribed in the nucleus but capable of residing in mitochondria in relatively low levels (e.g., RMRP, RPPH1, TERC) were undetectable (not shown). The abundance of reads of mt-RNAs found in EVs (from HC, MCI, and AD donors), along the mitochondrial chromosome were visualized in the UCSC Genome Browser (Figure 2D). As observed, the mitochondrial RNA reads in EVs from HC individuals (gray) were lower than the mitochondrial RNA reads from MCI (blue) or AD (pink). These findings indicate that EVs from persons with MCI and AD have higher levels of mitochondrial RNAs than EVs from healthy persons.

Validation of mt-RNAs

The observation that mt-RNAs were widely elevated in EVs from MCI and AD individuals, as determined from RNA-seq analysis, prompted us to validate these changes using RT-qPCR analysis in a new cohort. We obtained plasma samples from an additional five individuals per group (HC, MCI, and AD) in Cohort 2, section “Materials and Methods”; Figure 3A), isolated EVs, extracted RNAs, and performed RT-qPCR analysis using specific primer pairs. As shown in Figure 3B, all transcripts tested (MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MT-ATP6, MT-ATP8, MT-CYTb, MT-CO1, MT-CO2, and MT-CO3 mRNAs, and MT-RNR1 rRNA) were significantly more abundant in EV RNAs obtained from individuals with MCI compared to AD (but not from individuals with mild AD dementia) than in EV RNA from HC individuals. Measurement of GAPDH mRNA, which encodes the housekeeping protein GAPDH, showed that the levels of this cytoplasmic mRNA were unchanged among these groups. In summary, in EVs from patients with MCI due to AD, the levels of mt-RNAs are robustly and significantly more abundant.

Brain Cell Types Release EV-Containing mt-RNA Upon Stress

Given the strong rise in mt-RNAs in EVs from MCI and AD individuals, we hypothesized that this elevation might result from the toxic environment in the AD brain from the accumulation of Aβ and other neurotoxic aggregates causing oxidative damage. Of course, EVs enriched in mt-RNAs may also originate from other tissues and organs of MCI and AD individuals, since we were unable to establish the tissue of origin (see section “Discussion”). Thus, we set out to test the hypothesis that brain cells present in the vicinity of neurotoxic stimuli (Aβ and oxidants) might participate in the release of EVs bearing mt-RNAs, and that these EVs would then cross the blood-brain barrier (BBB) and appear in plasma. To study this possibility, we employed cultured human astrocytoma 1321N1 cells, microglia (HMC3) cells, and neuroblastoma M17 [SK-N-BE(2)-M17] cells, as well as mouse primary neurons, and exposed them to different doses of oligomeric Aβ (specifically Aβ1-42, “Aβ42”) and the oxidant hydrogen peroxide (H2O2) continuously for 3 days, whereupon we isolated EVs from the conditioned media and extracted RNA for RT-qPCR analysis of mt-RNAs. Control EVs were prepared after incubating cells with filtered PBS instead of Aβ42 oligomers or H2O2. In control reactions, the presence of abundant transcripts often found in EVs (e.g., GAPDH and ACTB mRNAs) and the absence of transcripts often undetectable in EVs (e.g., CDKN1A and CDKN2A mRNAs) were confirmed by RT-qPCR analysis (Supplementary Figure S2A); mitochondrial DNA was also undetectable (not shown).

As shown in Figure 4A, all three Aβ42-treated populations released EVs containing more mt-RNAs than untreated cells. Both H1321N1 cells (treated with 1 μM Aβ42) and M17 cells (treated with 5 μM Aβ42) showed significantly higher levels of ND1, ND6, COI, ATP6, and CYTB mRNAs, and RNR1 rRNA upon Aβ treatment compared with cells treated with vehicle alone. Microglial cells (HMC3) showed a similar trend but to a lesser extent (Figure 4A). Similarly, treatment with H2O2 also increased levels of mt-RNAs in EVs released by astrocytoma 1321N1 cells (Figure 4B) and from neuroblastoma M17 cells (not shown), although not from microglia (Figure 4B). We also observed that H2O2 treatment increased mt-RNA levels in EVs from mouse primary neurons (Figure 4B). Together, these findings support the notion that stressors such as Aβ42 and the oxidant H2O2 trigger the release of EVs containing high levels of mt-RNAs.

Other Mitochondrial Contents in EVs in Response to Stress

The above findings support the notion that in the neurotoxic environment of the AD brain, astrocytes, microglia, and neurons might release more EVs that contain mt-RNA, possibly because mitochondrial fragments are released in such EVs. To further
test this hypothesis, we investigated whether EVs released in these cultured models (Aβ42- and H2O2-treated brain cells) contained mitochondria or mitochondria fragments as seen using transmission electron microscopy (TEM) analysis; control EVs were again collected after incubating cells with filtered PBS instead of Aβ42 oligomers or H2O2. For this analysis, we focused on 1321N1 astrocytoma cells treated with toxic agents. Following Aβ42 treatment and collection and preparation of EVs, TEM images did not reveal intact mitochondria in the EV preparations but did detect many membranous remnants inside EVs of different sizes (arrows), which could be mitochondria or other organelles.

To ascertain whether the structures identified by TEM might include mitochondrial material, we performed Western blot analysis to assess the levels of mitochondrial proteins in EVs under stress conditions. Consistent with the mt-RNA analysis, we also detected higher levels of mitochondrial proteins in EVs released by 1321N1 astrocytoma cells treated with Aβ42.
and H$_2$O$_2$ relative to untreated cells (Figure 5B). As shown, the levels of TOMM20 (translocase of outer mitochondrial membrane 20) increased in astrocytoma-released EVs upon Aβ42 and H$_2$O$_2$ treatments; the levels of TOMM20 in whole-cell lysates were not significantly altered by Aβ42 treatment but decreased following H$_2$O$_2$ treatment. The levels of mitochondrial...
FIGURE 3 | Validation of mt-RNAs in EVs by RT-qPCR analysis. (A) Subject characteristics of additional individual human blood donors for RNA-sequencing validation. Five samples were collected in each group as in Figure 1A. Mean age is 75.8 years for HC, 66.4 years for MCI, and 74.6 years for AD. (B) RT-qPCR analysis of human mt-RNAs (MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MT-ATP6, MT-ATP8, MT-CYTB, MT-CO1, MT-CO2, MT-CO3 mRNAs, and MT-RNR1 rRNA) and GAPDH mRNA. Data represent all individuals of each group, 5 HC, 5 MCI, and 5 AD.
FIGURE 4 | Treatment with Aβ42 and H$_2$O$_2$ increases mt-RNAs in EVs. (A) RT-qPCR analysis of mt-RNAs in EVs obtained from human astrocytoma, microglia, and neuroblastoma cells after treatments with Aβ42 oligomers, as indicated (section “Materials and Methods”). (B) RT-qPCR analysis of mt-RNAs in EVs obtained from astrocytoma, microglia, or primary mouse neurons after treatments with H$_2$O$_2$ as indicated (section “Materials and Methods”). Data are normalized to GAPDH mRNA values and represent the means ± SEM from three independent experiments. *P < 0.05, **P < 0.01.
FIGURE 5 | Treatment of astrocytoma with Aβ42 and H₂O₂ increases the presence of inclusions and mitochondrial proteins in EVs. (A) EVs were isolated from astrocytoma cells treated with 1 µM Aβ42 for 3 days. Representative transmission electron microscopy (TEM) images showing inclusions of structures (arrows) consistent with mitochondria fragments. Black bars, size scale. (B) Western blot analysis of COXIV, OPA1, TOMM20, GAPDH, CD81, and CD63 using whole-cell lysates (‘Cell’) and EVs obtained from astrocytes after the indicated treatments.
cytochrome c oxidase subunit IV (COX IV) increased upon H$_2$O$_2$ treatment but not by Aβ42 treatment (Figure 5B), while the levels of the mitochondrial protein optic atrophy protein 1 (OPA1) increased in EVs from Aβ42-treated cells but were undetectable in EVs from H$_2$O$_2$-treated cells. CD81, a canonical EV marker used as positive control, was only detected in EVs and not in whole-cell lysates ('Cells', Figure 5B). GAPDH signals were included as control for loading of whole-cell lysates; other loading assessments are shown in Supplementary Figures S2B,C. Together, these data support the possibility that mt-RNAs and mitochondrial proteins found in EVs may be released as mitochondrial fragments from damaged cells (Figure 6). The data further suggest that the increased levels of mt-RNAs recovered from plasma EVs of MCI and AD individuals could originate (at least in part) from mitochondrial fragments of brain cells released into EVs in regions of neurotoxicity.

**DISCUSSION**

Here, we investigated the RNA content of circulating EVs isolated from the blood of HC, MCI, and AD individuals and discovered a striking enrichment in mitochondrial RNAs in the MCI and AD groups (Figure 2). This finding suggests that the levels of mt-RNAs in circulating EVs could be developed into a novel diagnostic biomarker for early AD. Using a different cohort of plasma donors, we carried out RT-qPCR analysis to validate the RNA-seq differences between HC and MCI (although not the difference from HC to AD due to high variability), further suggesting that EV-associated mt-RNAs may be used as AD biomarkers, especially for earlier stages of the disease (Figure 3).

AD is the result of multiple overlapping pathogenic processes, including mitochondrial dysfunction. AD lesions, particularly Aβ aggregates, trigger the production of reactive oxygen species (ROS) and damaged mitochondria, which in turn causes oxidative injury (Shelat et al., 2008), and at the same time, mitochondrial dysfunction has been documented extensively in AD brain (Beal, 1998 and Beal, 2005). The discovery that circulating EVs of AD individuals contain markedly higher levels of mt-RNAs raises a pressing question: what cells generate these EVs rich in mt-RNAs? The use of cell type-specific markers on the surface of EVs to isolate EV sub-populations could help resolve this question, but, since immunocapture methodologies result in >10-fold lower concentrations of EVs (Mustapic et al., 2017) and correspondingly lower RNA levels, it was not feasible to use them for this study, which relied on RNA-seq analysis. Our effort to immunocapture EVs enriched for neuronal origin using
anti-L1CAM antibodies (Suire et al., 2017) resulted in a yield of EVs that was too low to allow amplification of even the most abundant RNAs; similar limitations were anticipated with the detection of the astrocyte-specific EV marker GLAST [astrocyte cell surface antigen-1 (ACSA-1)] (not shown). Accordingly, it is important to recognize that the mt-RNA-bearing EVs identified here might also originate in other tissues and organs outside of the brain.

As an alternative approach, we sought to obtain preliminary answers through experiments using cultured cells from brain, as we posited that brain cells might be the source of EVs with elevated mt-RNAs in AD and MCI. To model the neurotoxic niche in the vicinity of Aβ plaques in culture, we treated different brain cells with toxic Aβ42 oligomers or oxidants, and quantified the RNA content of the EVs released. As documented in Figure 4, human cells derived from microglia and astrocytes, as well as neurons from mouse (primary neurons) and human (neuroblastoma cells) exposed to Aβ42 oligomers or H2O2 for 3 days released EVs that were enriched in mt-RNAs. These results support the notion that microglia, astrocytes, and neurons from the neurotoxic niche may contribute to the population of circulating EVs bearing high levels of mt-RNAs. Although the magnitude of mt-RNA enrichment in EVs from Aβ42 or H2O2-treated cells was far lower than that observed in plasma of AD individuals, the time scales in each case are very different, as cultured cells were only exposed for 3 days while the brain cells of individuals with AD are exposed to neurotoxic stimuli for decades and their EVs potentially reach a high steady concentration in plasma over months or years. It is also certainly possible that other cell types in the body of individuals with AD may release these EVs instead or in addition to brain cells. Further technical development to capture specific cell EVs with higher yield may further reveal the source of mt-RNA-enriched circulating EVs. In addition to mt-RNAs, EVs released from glial and neuronal cells challenged with Aβ42 or H2O2 contained membraneous remnants consistent with mitochondrial fragments (Figure 5) as well as mitochondrial proteins which also warrant testing as biomarkers. The specific size and composition of the mt-RNA-bearing EVs remain to be studied in molecular detail. However, these EVs do not appear to include apoptotic bodies, as we did not observe apoptotic markers (cleaved caspase 3 or cleaved PARP) in the cell populations and the diameter of the EVs (<600 nm) was smaller than the typical diameter (< 1,000 nm) of apoptotic bodies (Supplementary Figure S3). It remains to be determined if EVs in AD plasma samples contain mitochondrial proteins or fragments similar to those found in EVs in culture.

Why might neurotoxic stimuli trigger the release of mitochondrial content in cultured cells? We postulated that cells might remove damaged mitochondria in order to prevent further oxidative injury. The removal of damaged mitochondria can be achieved internally by the cell through mitophagy, a form of autophagy specialized in breaking down dysfunctional mitochondria (Youle and Narendra, 2011; Yin et al., 2016; Montava-Garriga and Ganley, 2020; Wang et al., 2020). Such elimination of dysfunctional mitochondria through mitophagy and the mitochondrial-lysosomal axis become aberrant during aging (Picca et al., 2019a). Therefore, in a chronic disease developing against the background of aging, such as AD, perhaps the burden of damage is such that removal of dysfunctional mitochondria from the cell by encapsulating them in EVs may be chosen to accelerate this clearance.

EVs have also been proposed to function in intercellular communication and transport cargo from one cell or tissue to another, possibly spanning long distances. Whether EVs from AD individuals may have a signaling role is unknown. However, it is unlikely that the mt-RNAs being transported in EVs can function in protein translation, as the mt-RNA in our EVs are fragmented (Figures 1C,D). Nonetheless, small RNAs, peptides, bioactive lipids, and small molecules present in EVs from MCI and AD plasma might function as signaling factors in cell-to-cell communication (El Andaloussi et al., 2013; Thompson et al., 2016), but their nature and function have not been comprehensively studied at present.

Other pathologies have also been associated with the presence of mitochondrial contents in EVs. For example, sera from children with autism spectrum disorder contain a significant amount of mt-DNA compared with the normotypic controls (Tsilioni and Theoharides, 2018), astrocytes release mitochondrial particles after stroke (Hayakawa et al., 2016), and EVs containing mitochondria components were proposed as biomarkers in PD (Picca et al., 2019b). In addition, mitochondrial membrane proteins were also higher in melanoma-derived EVs compared with control EVs (Jang et al., 2019) and in chemoresistant breast cancer (Sansone et al., 2017). Adding mt-RNA and other RNAs to protein biomarkers may further increase the diagnostic performance of EV biomarkers in AD. As the presence of mitochondrial material in EVs is increasingly being associated with various diseases, it will be important to comprehensively study mitochondrial molecules as biomarkers of disease and aging.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/geo/, GSE153881.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institutional Review Board NIA NIH. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

KK, QM, DK, and MG conceived the manuscript. KK QM, OP, MM, AC, EE, RM, WW, JN, and MD performed the experiments. GK and SD performed the bioinformatic analysis. LC and KA...
contributed intellectually. KK, QM, DK, and MG wrote the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by the National Institute on Aging Intramural Research Program, National Institutes of Health, by the research fund of Chungnam National University, and by grant NRF-2020R1C1C1010869 to KK.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2020.581882/full#supplementary-material

**REFERENCES**

Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 7, 270–279.

Andaloussi, S. E. L., Mager, I., Breakefield, X. O., and Wood, M. J. (2013). Extracellular vesicles: biology and emerging therapeutic opportunities. *Nat. Rev. Drug Discov.* 12, 347–357. doi: 10.1038/nrd3978

Armstrong, D., and Wildman, D. E. (2018). Extracellular vesicles and the promise of continuous liquid biopsies. *J. Pathol. Transl. Med.* 52, 1–8. doi: 10.4132/jptm.2017.05.21

Athauda, D., Gulyani, S., Karnati, H. K., Li, Y., Tweedie, D., Mustapic, M., et al. (2019). Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with parkinson disease: a secondary analysis of the Exenatide-PD Trial. *JAMA Neurol.* 76, 420–429. doi: 10.1001/jamaneurol.2018.4304

Beal, M. F. (1998). Mitochondrial dysfunction in neurodegenerative diseases. *Biochim. Biophys. Acta.* 1406, 211–223.

Beal, M. F. (2005). Oxidative damage as an early marker of Alzheimer's disease and mild cognitive impairment. *Neurobiol. Aging* 26, 585–586. doi: 10.1016/j.neurobiolaging.2004.09.022

Bhargava, P., Nogueras-Ortiz, C., Chawla, S., Back, R., Jorgensen, M. M., and Kapogiannis, D. (2019). Altered levels of toll-like receptors in circulating extracellular vesicles in multiple sclerosis. *Cells* 8:1058. doi: 10.3390/cells8091058

Budnik, V., Ruiz-Cana, C., and Wendler, F. (2016). Extracellular vesicles round off communication in the nervous system. *Nat. Rev. Neurosci.* 17, 160–172. doi: 10.1038/nrn.2015.29

Caruso Bavisotto, C., Scalia, F., Marino Gammazza, A., Carlisi, D., Bucchieri, F., Conway de Macario, E., et al. (2019). Extracellular vesicle-mediated cell-cell communication in the nervous system: focus on neurological diseases. *Int. J. Mol. Sci.* 20:434. doi: 10.3390/ijms20020434

Cha, D. J., Mengel, D., Mustapic, M., Liu, W., Selkoe, D. J., Kapogiannis, D., et al. (2019). miR-212 and miR-132 are downregulated in neurally derived plasma exosomes of Alzheimer’s patients. *Front. Neurosci.* 13:1208. doi: 10.3389/fnins.2019.01208

Chawla, S., Gulyani, S., Allen, R. P., Earley, C. J., Li, X., Van Zijl, P., et al. (2019). Extracellular vesicles reveal abnormalities in neuronal iron metabolism in restless legs syndrome. *Sleep* 42:zs079.

Cheng, L., Doeeke, J. D., Sharpeles, R. A., Villemagne, V. L., Fowler, C. J., Rembach, A., et al. (2015). Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropathological and neuroimaging assessment. *Mol. Psychiatry* 20, 1188–1196. doi: 10.1038/mp.2014.127

Coleman, B. M., and Hill, A. F. (2015). Extracellular vesicles—their role in the packaging and spread of misfolded proteins associated with neurodegenerative diseases. *Semin. Cell Dev. Biol.* 40, 89–96. doi: 10.1016/j.semcdb.2015.02.007

Dickhout, A., and Koenen, R. R. (2018). Extracellular vesicles as biomarkers in cardiovascular disease: chances and risks. *Front. Cardiaco. Med.* 5:13. doi: 10.3389/fcmva.2018.00113

Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., et al. (2016). Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. *Alzheimers Dement.* 12, 292–323.

Goetzl, E. J., Mustapic, M., Kapogiannis, D., Eitan, E., Lobach, I. V., Goetzl, L., et al. (2016). Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease. *FASEB J.* 30, 3853–3859. doi: 10.1096/fj.201600756e

Goetzl, E. J., Schwartz, J. B., Abner, E. L., Jicha, G. A., and Kapogiannis, D. (2018). High complement levels in astrocyte-derived exosomes of Alzheimer disease. *Ann. Neurol.* 83, 544–552. doi: 10.1002/ana.25172

Hayakawa, K., Esposito, E., Wang, X., Terasaki, Y., Liu, Y., Xing, C., et al. (2016). Transfer of mitochondria from astrocytes to neurons after stroke. *Nature* 535, 551–555. doi: 10.1038/nature18928

Hill, A. F. (2019). Extracellular vesicles and neurodegenerative diseases. *J. Neurosci.* 39, 9269–9273. doi: 10.1523/jneurosci.0147-18.2019

Holm, M. M., Kaiser, J., and Schwab, M. E. (2018). Extracellular vesicles: multimodal envys in neural maintenance and repair. *Trends Neurosci.* 41, 360–372. doi: 10.1016/j.tins.2018.03.006

Jackson, C. L., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., et al. (2016). A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. *Neurology* 87, 539–547. doi: 10.1212/wnl.0000000000002923

Jang, S. C., Crescittelli, R., Cijetkovic, A., Belgrano, V., Olofsen Bagge, R., Sundfeldt, K., et al. (2019). Mitochondrial protein enriched extracellular vesicles discovered in human melanoma tissues can be detected in patient plasma. *J. Extracel. Vesicles* 8:1635420. doi: 10.1080/20013078.201635420

Jepesen, D. K., Fenix, A. M., Franklin, J. L., Higginbotham, J. N., Zhang, Q., Zimmerman, L. J., et al. (2019). Reassessment of exosome composition. *Cell* 177, 428–445.e18.

Kapogiannis, D., Dobrowoynly, H., Tran, J., Mustapic, M., Frodl, T., Meyer-Lotz, G., et al. (2019a). Insulin-signaling abnormalities in drug-naive first-episode schizophrenia: transduction protein analyses in extracellular vesicles of putative neuronal origin. *Eur. Psychiatry* 62, 124–129. doi: 10.1016/j.eurpsy.2018.09.012

Kapogiannis, D., Mustapic, M., Shardell, M. D., Berkowitz, D. K., Diehl, T. C., Spangler, R. D., et al. (2019b). Association of extracellular vesicle biomarkers with Alzheimer disease in the Baltimore longitudinal study of aging. *JAMA Neurol.* 76, 1340–1351. doi: 10.1001/jamaneurol.2019.2462

Lane, R. E., Korbie, D., Hill, M. M., and Trau, M. (2018). Extracellular vesicles as circulating cancer biomarkers: opportunities and challenges. *Clin. Transl. Med.* 7:4.

Lee, S., Mankhong, S., and Kang, J. H. (2019). Extracellular vesicle as a source of alzheimer's biomarkers: opportunities and challenges. *Int. J. Mol. Sci.* 20:1728. doi: 10.3390/ijms20071728

Macintyre, E. H., Wintersgill, C. J., and Thormar, H. (1972). The establishment of continuous liquid biopsies. *J. Pathol. Transl. Med.* 11, 7–13.

Mansur, R. B., Delgado-Peraza, F., Subramaniapillai, M., Lee, Y., Iacubucci, M., Rodrigues, N., et al. (2020). Extracellular vesicle biomarkers reveal inhibition of neuroinflammation by infliximab in association with antidepressant response in adults with bipolar depression. *Cells* 9:895. doi: 10.3390/cells9040895

McKhan, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R. Jr., Kawas, C. H., et al. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the National institute on aging-Alzheimer's
association workgroups on diagnostic guidelines for Alzheimer’s disease. 

Alzheimers Dement. 7, 263–269.

Montava-Garriga, L., and Ganley, I. G. (2020). Outstanding questions in 

mitophagy: what we do and what we don’t know. J. Mol. Biol. 432, 206–230. doi: 

10.1016/j.jmb.2019.08.024

Mullins, R. J., Mustapic, M., Chia, C. W., Carlson, O., Gulyani, S., Tran, J., 

et al. (2019). A pilot study of exenatide actions in Alzheimer’s disease. Curr. 

Alzheimer Res. 16, 741–752. doi: 10.2174/1567205016666190913155950

Mustapic, M., Eitan, E., Werner, J. K. Jr., Berkowitz, S. T., Lazaropoulos, M. P., 

Tran, J., et al. (2017). Plasma extracellular vesicles enriched for neuronal origin: 

a potential window into brain pathologic processes. Front. Neurosci. 11:278. 

doi:10.3389/fnins.2017.00278

Picca, A., Guerra, F., Calvani, R., Bucci, C., Lo Monaco, M. R., Bentivoglio, 

A. R., et al. (2019a). Mitochondrial dysfunction and aging: insights from the 
analysis of extracellular vesicles. Int. J. Mol. Sci. 20:805. doi:10.3390/ijms2004 

0805

Picca, A., Guerra, F., Calvani, R., Bucci, C., Lo Monaco, M. R., Bentivoglio, 

A. R., et al. (2019b). Mitochondrial-derived vesicles as candidate biomarkers in 
parkinson’s disease: rationale, design and methods of the exosomes in Parkinson 
disease (EXPAND) study. Int. J. Mol. Sci. 20:2373. doi:10.3390/ijms20102373 

Raposo, G., and Stoorvogel, W. (2013). Extracellular vesicles: exosomes, 
microvesicles, and friends. J. Cell Biol. 200, 373–383. doi: 10.1083/jcb. 

201211138

Sansone, P., Savini, C., Kurelac, I., Chang, Q., Amato, L. B., Strillacci, A., et al. 

(2017). Packaging and transfer of mitochondrial DNA via exosomes regulate 

escape from dormancy in hormonal therapy-resistant breast cancer. Proc. Natl. 

Acad. Sci. U.S.A. 114, E9066–E9075.

She łat, P. B., Chalimoniuk, M., Wang, J. H., Strosznajder, J. B., Lee, J. C., Sun, A. Y., 

et al. (2008). Amyloid beta peptide and NMDA induce ROS from NADPH 

oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. 

J. Neurochem. 106, 45–55. doi:10.1111/j.1471-4159.2008.05347.x

Shi, M., Sheng, L., Stewart, T., Zabetian, C. P., and Zhang, J. (2019). New windows into 

the brain: central nervous system-derived extracellular vesicles in blood. 

Prog. Neurobiol. 175, 96–106. doi:10.1016/j.pneurobio.2019.01.005

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, 

A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National institute on aging—Alzheimer’s 

association workgroups on diagnostic guidelines for Alzheimer’s disease. 

Alzheimers Dement. 7, 280–292.

Stahl, A. L., Johansson, K., Mossberg, M., Kahn, R., and Karpman, D. (2019). 

Exosomes and microvesicles in normal physiology, pathophysiology, and renal 

diseases. Pediatr. Nephrol. 34, 11–30. doi:10.1007/s00467-017-3816-z 

Suire, C. N., Eitan, E., Shaffer, N. C., Tian, Q., Studenski, S., Mattson, M. P., 
et al. (2017). Walking speed decline in older adults is associated with elevated 

pro-BDNF in plasma extracellular vesicles. Exp. Gerontol. 98, 209–216. doi: 

10.1016/j.exger.2017.08.024

Thompson, A. G., Gray, E., Heman-Ackah, S. M., Mager, I., Talbot, K., Andaloussi, 

S. E., et al. (2016). Extracellular vesicles in neurodegenerative disease - 

pathogenesis to biomarkers. Nat. Rev. Neurol. 12, 346–357. doi:10.1038/ 
nrneurol.2016.68

Tsiiloni, I., and Theoharides, T. C. (2018). Extracellular vesicles are increased in 

the serum of children with autism spectrum disorder, contain mitochondrial 

dNA, and stimulate human microglia to secrete IL-1beta. J. Neuroinflammation 

15:239.

van Niel, G., D’Angelo, G., and Raposo, G. (2018). Shedding light on the cell 
biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213–228. doi: 

10.1038/nrm.2017.125

Wang, L., Qi, H., Tang, Y., and Shen, H. M. (2020). Post-translational modifications 
of key machinery in the control of mitophagy. Trends Biochem. Sci. 45, 58–75. 

doi: 10.1016/j.tibs.2019.08.002

Weller, J., and Budson, A. (2018). Current understanding of Alzheimer’s disease 
diagnosis and treatment. F1000Res. 7:1161. doi:10.12688/f1000research. 

14506.1

Yin, Z., Pascual, C., and Klionsky, D. J. (2016). Autophagy: machinery and 

regulation. Microb. Cell 3, 588–596. doi:10.15698/mic2016.12.546

Youle, R. J., and Narendra, D. P. (2011). Mechanisms of mitophagy. Nat. Rev. Mol. 

Cell Biol. 12, 9–14.

Zhao, Q., Lu, D., Wang, J., Liu, B., Cheng, H., Mattson, M. P., et al. (2019). Calcium 
dysregulation mediates mitochondrial and neurite outgrowth abnormalities in 

SOD2 deficient embryonic cerebral cortical neurons. Cell Death Differ. 26, 

1600–1614. doi: 10.1038/s41418-018-0230-4

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Kim, Meng, Perez de Acha, Mustapic, Cheng, Eren, Kundu, Piao, Munk, Wood, De, Noh, Delannoy, Cheng, Abdelmohsen, Kaspojiannis and Gorospe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.